Hudson Bay Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hudson Bay Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.09M	Hold	50,000	–	–	﹤0.01%	863
2025 Q4	$1.08M	Hold	50,000	–	–	﹤0.01%	787
2025 Q3	$964K	Sell	50,000 -45,300	-48%	-$808K	﹤0.01%	865
2025 Q2	$1.63M	Buy	+95,300	New	+$4.07M	0.01%	852
2023 Q4	–	Sell	-50,100	Closed	-$6.07M	–	881
2023 Q3	$6.07M	Buy	+50,100	New	+$5.66M	0.05%	247
2018 Q1	–	Sell	-225,000	Closed	-$12.5M	–	856
2017 Q4	$12.5M	Sell	225,000 -180,800	-45%	-$9.58M	0.27%	60
2017 Q3	$18.4M	Sell	405,800 -451,000	-53%	-$18M	0.46%	45
2017 Q2	$28.9M	Buy	856,800 +321,700	+60%	+$10.5M	0.58%	30
2017 Q1	$15.8M	Sell	535,100 -220,000	-29%	-$6.81M	0.21%	94
2016 Q4	$20.7M	Buy	755,100 +687,700	+1,020%	+$27.6M	0.43%	44
2016 Q3	$4.14M	Sell	67,400 -1,035,300	-94%	-$31.3M	0.1%	161
2016 Q2	$21M	Buy	+1,102,700	New	+$20.4M	0.65%	22

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management's SRPT Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 5.5% in Q1 2026, selling an estimated $290K and leaving 260,000 shares worth $5.66M. The position accounts for 0.02% of the portfolio, ranked #476.

Hudson Bay Capital Management first reported a position in SRPT in Q2 2016 and has held it in 27 quarters since. The position peaked at $33.1M in Q3 2016. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Hudson Bay Capital Management held 260,000 shares of Sarepta Therapeutics worth $5.66M as of Q1 2026.
Hudson Bay Capital Management sold 15,000 Sarepta Therapeutics shares in Q1 2026, an estimated $290K.
Sarepta Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q1 2026, its #476 holding.
Hudson Bay Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 27 quarters since.
Hudson Bay Capital Management's Sarepta Therapeutics position peaked at $33.1M in Q3 2016.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.